Últimas noticias sobre Asana (NYSE:ASAN) Bolsa

Asana

Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.

ASAN

DLTR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: DLTR, PD, DKS, ASAN y HPE.

5 acciones en el foco este miércoles: DLTR, PD, DKS, ASAN y HPE

Asana Inc

ASANTE Inc

Asante Gold Corp

Asanuma Corp

In a significant development for psychedelics research, a <a href="https://www.benzinga.com/topic/drug-enforcement-administration">Drug Enforcement Administration (DEA)</a> administrative law judge has rejected the agency's request to block key witnesses and evidence in an upcoming hearing. The case, <a href="https://www.benzinga.com/markets/cannabis/24/08/40613739/dea-schedules-hearing-on-proposed-ban-of-psychedelics-doi-doc-amid-researchers-concerns">set for November</a>, challenges the DEA's proposed ban on two psychedelic compounds, DOI and DOC, which are used in research.
<h3 class="wp-block-heading">DEA&#8217;s Argument On Irrelevance Of Testimonies Rejected</h3>
The DEA sought to exclude certain experts and materials, claiming they were "irrelevant" to the case. However, as Marijuana Moment <a href="https://www.marijuanamoment.net/dea-judge-denies-agencys-request-to-block-witnesses-in-hearing-challenging-proposed-psychedelics-ban/">reported</a>, administrative Law Judge Paul Soeffing <a href="https://www.documentcloud.org/documents/25245031-dea-alj-doi-doc-evidence?responsive=1&amp;title=1">denied</a> the motion, stating it was premature to determine the relevance of the testimony. This is seen as a partial win for groups like Students for Sensible Drug Policy (SSDP) and Panacea Plant Sciences (PPS), which oppose the ban.
The hearing aims to shed light on the proposed ban, which opponents say lacks evidence of abuse potential or health risks. Researchers argue there&#8217;s insufficient justification for classifying DOI and DOC as high-risk substances, as scientific literature shows no documented deaths or significant adverse reactions solely from these compounds. Studies over the past 35 years suggest DOI and DOC may effectively treat chronic pain, opioid and alcohol addiction and other mental health disorders.
<h3 class="wp-block-heading">Advocates Speak Out Against Schedule I Designation</h3>
Kat Murti, executive director of SSDP, expressed relief at the judge's decision. "The DEA is trying to force medical research into the dark ages by criminalizing DOI and DOC—essential research chemicals in pre-clinical psychiatry and neurobiology." She added that the judge's decision is "a victory not only for scientific integrity but for the tens of thousands of Americans suffering from depression, anxiety, and chronic pain."
David Heldreth, CEO of PPS, echoed these sentiments. "We hope the rest of the hearing continues to go our way." Heldreth and his organization <a href="https://www.benzinga.com/markets/cannabis/22/08/28654017/deas-latest-proposal-for-psychedelics-banning-gets-archived">have been at the forefront</a> of the legal challenge against the DEA, fighting for the continued use of DOI and DOC in research.
<h3 class="wp-block-heading">An Ongoing Challenge</h3>
This resolution is part of a <a href="https://www.benzinga.com/markets/cannabis/22/08/28606682/deas-psychedelic-drugs-banning-attempt-this-are-the-two-hallucinogens-under-discussion">longer battle</a> between the DEA and the scientific community. The DEA&#8217;s action to place DOI and DOC in <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I</a> of the Controlled Substances Act <a href="https://www.benzinga.com/government/24/04/38053487/dea-revisits-proposed-ban-on-two-psychedelic-compounds-researchers-disagree-insist-on-hearings">dates back to 2018</a>, and has been met with <a href="https://www.benzinga.com/markets/cannabis/24/07/39975673/dea-faces-backlash-over-psychedelics-ban-proposal-from-student-advocacy-group">significant pushback</a>. These compounds are unscheduled at the moment and have been pivotal in research aimed at treating conditions like chronic pain, addiction and mental health disorders. Opponents argue that a Schedule I designation would severely impede scientific research on these substances.
The hearing is scheduled to run from November 12-22, with a final meeting on November 25, as researchers and advocates continue their fight to prevent the ban on DOI and DOC.
Cover image made with AI.

Cannabis

Government

News

Psychedelics

Regulations

Legal

DEA Faces Setback As Judge Denies Request To Block Witnesses In Psychedelics Ban Hearing

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are trading lower Wednesday afternoon after an analyst reported that iPhone 16 orders were cut <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41350919/apple-analyst-predicts-a-september-quarter-revenue-beat-allays-fears-over-shorter-i">by around 10 million units</a>.
What To Know: Apple analyst Ming-Chi Kuo released a <a href="https://medium.com/@mingchikuo/iphone-16-orders-cut-by-around-10-million-units-for-4q24-1h25-no-evidence-yet-that-apple-48c126a33bc6">report</a> Wednesday afternoon suggesting that iPhone 16 orders were slashed by about 10 million units for the three-quarter period spanning the fourth quarter of 2024 through the first half of 2025.
The analyst said his latest industry survey showed that most of the cuts impact the non-Pro models. Given the cuts, Kuo expects <a href="https://www.benzinga.com/topic/iphone-16">iPhone 16</a> production in the second half of 2024 to total 84 million units, down from his prior forecast of around 88 million units.
Kuo also noted that iPhone SE4 production is slated to start in December. Production projections currently sit around 8.6 million units from launch to the end of the first quarter, he said. 
&#8220;Apple's iPhone revenue in 4Q24 may not fully reflect the impact of production cuts, as the gap between production and sell-through in 4Q23 was larger than in 4Q24, and the product mix in 4Q24 is more favorable (with increased production of the Pro Max model for Sep-Oct),&#8221; the analyst said.
&#8220;However, iPhone revenues are expected to come under pressure in 1H25 due to a YoY shipment decline and a less favorable product mix due to the launch of SE4.&#8221;
See Also: <a href="https://www.benzinga.com/success-stories/24/10/41441641/apple-ceo-tim-cook-says-apple-intelligence-will-make-products-profoundly-different-new-ai-technol">Apple CEO Tim Cook Says Apple Intelligence Will Make Products &#8216;Profoundly Different&#8217;: New AI Technology Will Get Consumers &#8216;On A Different Technology Curve&#8217;</a>
Kuo acknowledged that some are optimistic that Apple Intelligence could significantly boost iPhone shipments, but he suggested that order cuts show those expectations may not materialize in the short term.
&#8220;I believe that Apple is best positioned to succeed in on-device AI, and I am confident about the long-term potential for Apple Intelligence to become a popular paid service. However, significant growth in iPhone shipments will likely require further hardware innovation to accompany this AI development,&#8221; Kuo said.
Separately, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-10-23/goldman-apple-to-pay-89-million-following-cfpb-card-probe?sref=TBDibEcD&amp;embedded-checkout=true">reported </a>Wednesday that Apple and Goldman Sachs will have to pay over $89 million to settle an investigation into their credit card joint venture. 
The&nbsp;Consumer Financial Protection Bureau&nbsp;reportedly said Apple and Goldman &#8220;illegally sidestepped&#8221; their legal obligations for Apple Card borrowers. The agency ordered Goldman to pay at least $19.8 million in redress, as well as a civil money penalty of $45 million. Apple has been ordered to pay a $25 million civil money penalty. 
AAPL Price Action: <a href="http://benzinga.com/quote/aapl">Apple shares</a> were down 2.88% at $229.03 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Apple.

Movers

AAPL

Apple Stock Is Sliding Wednesday: What's Going On?

Scotiabank analyst Maher Yaghi maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Sector Perform and lowers the price target from $47.25 to $47.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Verizon Communications, Lowers Price Target to $47

WIIM

TZOO

Travelzoo shares are trading higher after the company announced better-than-expected Q3 EPS results and a repurchase program for up to one million shares.

Scotiabank analyst Cameron Bean maintains Topaz Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TPZ#TSX">TPZ</a>) with a Sector Outperform and raises the price target from C$34 to C$35.

TSX:TPZ

Scotiabank Maintains Sector Outperform on Topaz Energy, Raises Price Target to C$35

BTIG analyst Gray Powell maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Buy and raises the price target from $57 to $63.

BTIG Maintains Buy on Dynatrace, Raises Price Target to $63

McDonald&#39;s Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcd#NYSE">MCD</a>)&nbsp;has gained 24.2% in the past three months, outperforming the Zacks <a href="https://www.zacks.com/stocks/industry-rank/industry/retail-restaurants-160">Retail - Restaurants</a> industry, the Zacks <a href="https://www.zacks.com/stocks/industry-rank/sector/retail-wholesale-3">Retail-Wholesale</a> sector and the S&amp;P 500 Index, which rose 20.4%, 10.7% and 7.4%, respectively.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/82254.jpg?v=663129858" style="height:292px; width:624px" /> 
Image Source: Zacks Investment Research
The company is benefiting from its focus on enhancing customer experiences through its 4D Growth strategy and increased global franchise units. This, alongside an effective capital allocation strategy, has added to the uptrend, given its focus on maintaining shareholder value. 
MCD stock has also outperformed some major industry players, including Yum! Brands, Inc. YUM, Domino&#39;s Pizza, Inc. DPZ and Wingstop Inc. WING, in the past three months. In the said time frame, YUM and DPZ have rallied 5.9% and 0.5%, respectively, while WING has lost 1.2%.
<h3>Factors Driving MCD Stock</h3>
4D Growth Pillar: McDonald&#39;s continues unraveling new and improved ways to enhance customer experiences and drive growth. One of the company&#39;s primary tools to offer customers a more personalized and convenient experience is the 4D Growth Pillar, wherein 4D stands for Digital, Delivery, Drive Thru and Development. The Digital aspect encompasses the company&#39;s top-tier loyalty program available on its digital platform, which now has more than 150 million 90-day active users in approximately 50 markets globally.&nbsp; It anticipates 90-day active users to reach 250 million and annual loyalty system-wide sales to reach $45 billion by 2027. 
Regarding the Delivery and Drive Thru aspects, the company offers delivery services through McDelivery or third-party delivery providers in about 100 global markets, which represent more than 85% of its restaurants. Considering drive-thrus under the delivery section, the company houses quite a number of drive-thru locations across the globe, with more than 27,000 drive-thru locations globally. With the increase in delivery sales mix over the past few years, mainly in Australia, Canada and the United States, and leveraging its long-term strategic partnerships with delivery providers, the company aims to offer seamless customer experiences. 
Considering the Development aspect, McDonald&#39;s is banking on increased demand patterns globally and increasing its foothold by boosting its presence in existing markets and by entering new ones. The company is planning to open more than 2,100 new restaurants globally in 2024, including 500 openings in the United States and International Operated Markets (IOM) segment and 1,600 (including nearly 1000 in China) inaugurations in the International Developmental Licensed (IDL) market. Furthermore, it aims to open 50,000 restaurants by 2027. 
Franchised Revenues Offer Stability: Among the total restaurants worldwide of McDonald&#39;s, 95% were franchised restaurants as of June 30, 2024. The company operates in three reportable segments, wherein the U.S. segment has about 95% franchised ownership mix, the IOM segment has 89% franchised ownership mix and the IDL segment has 98% franchised ownership mix. 
This asset-light business strategy, having more franchised store units across the world, makes its operations less susceptible to market volatility than the company running its outlets on its own. The diversity in market conditions and regulatory hurdles across different nations would make it difficult for MCD to handle operations. This business strategy will offer it higher profit margins and a stable source of revenues. During the first six months of 2024, about 60.5% of revenues came from franchised restaurants. 
Effective Capital Allocation Strategy: The company follows an effective capital allocation strategy, wherein it aims to utilize its free cash flow in new business opportunities, dividend payouts and share repurchases. MCD&#39;s way of prioritizing shareholder value apart from business investments is encouraging in the industry. 
Maintaining its history of increasing dividend payments for 47 consecutive years, McDonald&#39;s has again announced a hike in its quarterly cash dividend on Sept. 25, 2024. It raised its quarterly dividend by 6% to $1.77 per share ($7.08 per share annually) from $1.67 per share ($6.68 per share annually). The dividend is to be paid on Dec. 16, 2024 to shareholders as of Dec. 2.
<h3>Estimate Trend Favors McDonald&#39;s</h3>
The Zacks Consensus Estimate for MCD&#39;s third-quarter and 2024 earnings per share (ETF:EPS) has trended upward in the past seven days. The uptrend can be witnessed from the chart given below.
EPS Trend
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d9/82252.jpg?v=159574847" /> 
Image Source: Zacks Investment Research
<h2>MCD Trading Above 50 &amp; 200-Day SMA</h2>
Technical indicators suggest a continued strong performance for McDonald&#39;s. From the graphical representation given below, it can be observed that MCD stock is trading above both the 50-day simple moving average (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sma#NYSE">SMA</a>) and 200-day SMA, signaling a bullish trend. The technical strength underscores positive market sentiment and confidence in MCD&#39;s financial health and prospects.
50 &amp; 200-Day Moving Average
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/32/82255.jpg?v=162340666" /> 
Image Source: Zacks Investment Research
<h2>MCD Trading at a Discount</h2>
McDonald&#39;s is currently trading at a discount compared with the industry peers on a forward 12-month price-to-earnings (P/E) ratio basis. The discounted valuation indicates that despite the recent stock price increase in the past three months, it remains an attractive option for investors looking for a suitable entry point.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c5/82253.jpg?v=1631045805" /> 
Image Source: Zacks Investment Research
<h2>Hurdles to MCD&#39;s Momentum</h2>
The tailwinds discussed above is helping McDonald&#39;s to move through the ongoing macro challenges and inflationary risks. However, headwinds like soft comparable store sales and high costs and expenses are pulling back the growth prospects to some extent. 
Soft Comps: McDonald&#39;s is facing challenges regarding weaker comparable store sales growth. The company&#39;s comps are hurt mainly due to negative comparable guest counts witnessed in the U.S. market and negative comparable sales in France witnessed under the IOM segment. The international market&#39;s trends are unfavorable since customers are wary of discretionary spending given the ongoing market challenges. 
Under the IDL segment, the continued impact of the war in the Middle East and negative comparable sales in China have resulted in declining comps. For the first six months of 2024, comparable sales under this segment decreased 0.8%. 
High Cost &amp; Expenses: The persisting inflationary pressures are hurting the company&#39;s margins. During the first six months of 2024, the company&#39;s total operating costs and expenses escalated 4% year over year to $7 billion due to increased restaurant and occupancy expenses along with selling, general and administrative expenses. 
The company anticipates operating margin to remain pressurized in the near term with labor inflation expected to be in the high single digits in 2024.
<h2>Is it a Wise Decision to Add MCD to Your Portfolio Now?</h2>
As discussed above, despite the ongoing macro hurdles and inflationary risks, McDonald&#39;s is gaining momentum in this competitive industry through its top-tier business strategies. The core business strategies of the company highlight its aim of delivering enhanced and personalized customer experiences, making strategic investments in growth opportunities and maintaining a consistent shareholder value. 
With the goals set through 2027 and the recent take on the dividend hike, along with increased franchised units, the company seems to be well-positioned to move through the uncertainties and deliver an outperformance in the upcoming period. 
Thus, based on the overall discussion and the trends of technical indicators, it is suggested to the existing investors to hold on to this Zacks Rank #3 (Hold) company&#39;s shares for now, whereas new investors might want to wait for a more favorable entry point given high costs and weaker comparable store sales growth.
<a href="https://www.zacks.com/stock/news/2356040/mcdonald-s-stock-jumps-24-in-3-months-should-you-buy-sell-or-hold?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2356040">To read this article on Zacks.com click here.</a>

Restaurants

Trading Ideas

General

WING

McDonald's Stock Jumps 24% In 3 Months: Should You Buy, Sell Or Hold?

OKYO

OKYO Pharma shares are trading higher after the company announced it dosed its first patient in a clinical trial to meet Neuropathic Corneal pain.

Scotiabank analyst Orest Wowkodaw maintains Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) with a Sector Perform and lowers the price target from $53 to $52.

Scotiabank Maintains Sector Perform on Freeport-McMoRan, Lowers Price Target to $52

With less than two weeks to the <a href="https://www.benzinga.com/topic/election-day">ballot vote</a>, the debate around Florida's<a href="https://www.benzinga.com/markets/cannabis/24/10/41405555/floridas-cannabis-amendment-record-spending-unlikely-alliances-and-criticism-from-the-catholic-c"> Amendment 3 </a>is heating up. Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) CEO Kim Rivers came out swinging in an appearance on a WESH2 <a href="https://www.wesh.com/article/trulieve-ceo-anti-amendment-3-recreational-cannabis-ads-distortions/62684977">news report</a> in which she described the anti-cannabis ads running throughout the state as &#8220;distortions.&#8221;
Rivers has taken issue with the portrayal of Amendment 3 in <a href="https://www.benzinga.com/markets/cannabis/24/10/41405555/floridas-cannabis-amendment-record-spending-unlikely-alliances-and-criticism-from-the-catholic-c">political ads</a> that claim the measure would create a cannabis monopoly in the state. 
&#8220;The economic door to prosperity would be open to many,&#8221; Rivers stated, dismissing the suggestion that the amendment would only benefit large corporations like Trulieve. 
The initiative, she argues, is about broadening opportunities in an industry projected for <a href="https://www.benzinga.com/markets/cannabis/24/10/41335229/cannabis-industrys-130b-growth-potential-top-states-for-investment-as-financial-institutions-set">explosive growth</a>.
During a recent visit to one of Trulieve's 155 <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/markets/cannabis/24/07/39871979/floridas-medical-cannabis-market-sees-explosive-growth-ahead-of-november-legalization-ballot&amp;ved=2ahUKEwimgou_-qSJAxWrrJUCHULWIkgQFnoECBkQAQ&amp;usg=AOvVaw0aYsig6m9Yhjuv_bk1bdHr">dispensaries</a>, Rivers spoke to employees about the significance of the amendment, which would legalize recreational cannabis for adults over 21.
<h3 class="wp-block-heading">Addressing Child Safety Concerns</h3>
One of the central points of contention in the opposition's campaign is the claim that legalizing cannabis will expose children to products packaged to resemble candy. Rivers has been vocal in rebutting these assertions.
 &#8220;These are adult products, packaged for adults, sold to adults,&#8221; she said. 
Rivers explained that recreational cannabis, like medical marijuana, would adhere to strict packaging guidelines designed to prevent any appeal to children.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
Her point was reinforced by Trulieve Medical Director Dr. Terel Newton, who added, &#8220;You won't see bright colors, animals, or neon packaging that would attract kids.&#8221;
According to Rivers, these types of regulations would continue under an adult-use program, ensuring that products are marketed responsibly.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41365515/ron-desantis-pregnant-pigs-and-floridas-cannabis-legalization-battle-over-constitutional-amendme">Ron DeSantis, Pregnant Pigs And Florida&#8217;s Cannabis Legalization: Battle Over Constitutional Amendment Rages</a>
<h3 class="wp-block-heading">Fear Vs Facts</h3>
For Rivers, the campaign against Amendment 3 is built on fear rather than facts.
&#8220;And I would fully expect and anticipate that those laws and those restrictions will continue in the state of Florida with the adult use program,&#8221; she told the WESH reporter. I think it is really critical for folks to understand what this is and what this is not.&#8221; 
The fight against misleading ads and scary tactics in Florida had another <a href="https://www.benzinga.com/markets/cannabis/24/10/41411270/desantis-doubles-down-with-new-taxpayer-funded-anti-marijuana-ads-one-links-cannabis-to-domestic">recent episode</a> when Gov. Ron DeSantis leveraged the Florida Department of Education to fund a new ad campaign warning against cannabis. 
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41303141/fact-check-desantis-why-floridas-weed-legalization-does-not-mean-smoking-in-schools">Fact-Check DeSantis: Why Florida&#8217;s Weed Legalization Does Not Mean Smoking In Schools</a></li>
</ul>
Cover: Photo by <a href="https://pixabay.com/es/users/jessica45-2055892/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=1409763">jessica45</a> in <a href="https://pixabay.com/es//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=1409763">Pixabay</a>

Politics

Markets

TCNNF

Trulieve CEO Kim Rivers Calls Out 'Distortions' In Ads Opposing Florida's Cannabis Amendment

Scotiabank analyst Mario Saric maintains ALLIED PROPS REAL ESTATE INV TST (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AP#TSX">AP</a>) with a Sector Outperform and raises the price target from C$21 to C$22.

TSX:AP

Scotiabank Maintains Sector Outperform on ALLIED PROPS REAL ESTATE INV TST, Raises Price Target to C$22

<a href="https://x.com/mingchikuo/status/1849144029423997038" title="https://x.com/mingchikuo/status/1849144029423997038">https://x.com/mingchikuo/status/1849144029423997038</a>

TSLA

Analyst Ming-Chi Kuo Post On X, "Tesla survey and prediction updates: 1. The more affordable new model (dubbed "Model 2" by some) is unlikely to enter mass production until 2H25 at the earliest. 2. The Model Y refresh is expected to start mass production in 1Q25."

Apple Inc. is nearing production of updated MacBook Airs with M4 chips for release in early 2025, a follow-up to a wave of new Macs that are coming next week, according to people familiar with the matter.&nbsp;
<a href="https://www.bloomberg.com/news/articles/2024-10-23/apple-makes-headway-on-m4-macbook-air-and-plans-new-low-end-ipad?srnd=phx-technology&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-10-23/apple-makes-headway-on-m4-macbook-air-and-plans-new-low-end-ipad?srnd=phx-technology&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-10-23/apple-makes-headway-on-m4-macbook-air-and-plans-new-low-end-ipad?srnd=phx-technology&amp;embedded-checkout=true</a>

'Apple Makes Headway on M4 MacBook Air and Plans New Low-End iPad' - Bloomberg

JP Morgan analyst Mark Murphy maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Overweight and lowers the price target from $19 to $17.

PATH

JP Morgan Maintains Overweight on UiPath, Lowers Price Target to $17

JP Morgan analyst Brian Ossenbeck maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Overweight and lowers the price target from $181 to $178.

TFII

JP Morgan Maintains Overweight on TFI International, Lowers Price Target to $178

Analysts are weighing in after Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) on Tuesday reported worse-than-expected preliminary fourth-quarter results and suspended <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41493540/stock-of-the-day-starbucks-finds-support-at-94-will-a-bidding-war-force-stock-into-an-up">its guidance for 2025.&nbsp;</a>
The Details: In a surprise move, Starbucks reported <a href="https://www.benzinga.com/news/earnings/24/10/41468529/starbucks-stock-stumbles-after-company-reports-weak-preliminary-results-suspends-guidance">preliminary results</a> for the fourth quarter showing that it expects consolidated net revenues to decline 3% and global comparable sales to fall 7%. Starbucks also said it anticipates earnings of 80 cents per share, down 25% year-over-year.&nbsp;
KeyBanc Captial Markets analyst Eric Gonzalez said that though investors had braced for disappointing fourth-quarter results from Starbucks, they may not have been prepared for the "magnitude of the top- and bottom-line miss." 
Gonzalez did express confidence in the leadership of new CEO Brian Niccol and pointed to his successful tenure as CEO at Chipotle Mexican Grill.&nbsp;
BofA Securities analyst Sara Senatore also highlighted Niccol's successful turnaround of Chipotle and see him as "well-suited" for a Starbucks turnaround. BofA Securities reiterated its Buy rating and $117 price target and said the Starbucks brand "remains fundamentally strong."
Read Next: <a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a>
Stifel analyst Chris O'Cull echoed similar sentiments regarding the abilities of Niccol as CEO and said he is "zeroing in on the correct issues" in his "Back To Starbucks" strategy. Stifel maintained its Buy rating but lowered its price target from $110 to $105.&nbsp;
Looking ahead, Goldman Sachs analysts said they will be watching for more details on the "Back to Starbucks" plan in the company's earnings call on Oct. 30 after the closing bell. Goldman Sachs specifically will listen for more details on the company's pricing strategy, key marketing message and required store-level investments needed to address staffing issues and removing bottlenecks. 
Goldman Sachs analyst Christine Cho maintained Starbucks with a Buy rating and lowered the price target from $110 to $105.
Other analysts updated coverage on Starbucks as well:&nbsp;
<ul>
<li>TD Cowen analyst Andrew Charles reiterated a Buy rating and $110 price target.</li>
<li>UBS analyst Dennis Geiger maintained a Neutral rating but raised the price target from $85 to $95.</li>
</ul>
Starbucks will report its fourth-quarter results after the market close on Oct. 30, followed by a conference call at 5 p.m. ET.
SBUX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Starbucks shares are down 0.64% at $96.21 at the time of publication Wednesday.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

SBUX

Starbucks Analysts Bullish On CEO Brian Niccol After Tough Preannouncement: 'Zeroing In' On Right Issues

JP Morgan analyst Andrew Steinerman maintains Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) with a Neutral and lowers the price target from $70 to $69.

JP Morgan Maintains Neutral on Robert Half, Lowers Price Target to $69

On Tuesday, Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41466981/alto-neuroscience-reports-topline-results-from-a-phase-2b-trial-evaluating-alto-100-as-a-treatment" rel="noreferrer noopener">compared to placebo</a>.
The biomarker-defined major depressive disorder patient group treated with ALTO-100 did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo.
ALTO-100 did not demonstrate a benefit over the placebo on the pre-specified key secondary analyses.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38388220/treatment-patch-for-schizophrenia-newly-listed-alto-neuroscience-is-uniquely-positi" rel="noreferrer noopener">Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape</a>.
ALTO-100 continued to demonstrate a favorable safety and tolerability profile, with no new safety signals observed in this study compared to the previously completed clinical trials of ALTO-100.
<ul>
<li>The most common adverse events from the trial related to treatment with ALTO-100 were headache, nausea, and abnormal dreams – all of which were experienced at similar rates to placebo.</li>
</ul>
The company expects to complete an analysis of the full data set to determine the most appropriate next steps, if any, to further evaluate ALTO-100 in major depressive disorder.
ALTO-100 is also being evaluated as an adjunctive treatment in a Phase 2b study for bipolar depression.
The company expects its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40350770/alto-neuroscience-reports-second-quarter-2024-financial-results-and-recent-business-highlights" rel="noreferrer noopener">current cash position</a> of $194 million to fund planned operations into 2027 and through multiple upcoming clinical readouts, including two additional readouts in major depressive disorder, with ALTO-203 and ALTO-300 expected in the first half of 2025.
William Blair notes that despite the setback with ALTO-100, which may raise concerns among investors about Alto&#8217;s Precision Psychiatry Platform, the analysts do not consider this single failure to undermine the validity of their biomarker enrichment strategy.
The analyst is now focused on the upcoming ALTO-300 Phase 2b results in major depressive disorder (MDD), anticipated in the first half of 2025, for further insights.
&#8220;While data points draw increased scrutiny on the biomarker stratification approach, historically placebo-controlled MDD studies have been high-risk, and this one appears no different. Still, in our discussions with management, it remained confident in the stratification approach, and we will await a fuller dataset to better understand this optimism despite the negative Phase 2b readout.&#8221; William Blair analysts write.
The analyst maintains <a target="_blank" href="https://www.benzinga.com/quote/ANRO/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: At last check on Wednesday, ANRO stock was down 67.70% to $4.70.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41486650/coca-cola-q3-earnings-eps-beat-pricing-growth-offset-by-volume-decline-sees-10-q4-organic-revenue-g" target="_blank" rel="noreferrer noopener">Coca-Cola Q3 Earnings: EPS Beat, Pricing Growth Offset By Volume Decline, Sees 10% Q4 Organic Revenue Growth</a>.</li>
</ul>

Biotech

Health Care

ANRO

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

- Reuters Citing Spokesperson&nbsp;

Hershey Company Has Banned Use Of PFAS Chemicals Globally For Well Over A Decade

JP Morgan analyst Bill Peterson maintains Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) with a Overweight and lowers the price target from $170 to $168.

JP Morgan Maintains Overweight on Nucor, Lowers Price Target to $168

Asana Earnings: Don't Buy This Dip, Again

Asana sinks following latest earnings as multiple firms lower price targets

In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Asana (ASAN – Research Report), with a price target of...

JMP Securities Reaffirms Their Buy Rating on Asana (ASAN)

Asana: Challenges Reflected In Bargain Share Price, But Sales Momentum Is Slowing (Rating Downgrade)

Smartsheet's Buyout Will Likely Improve Your Workflow Returns

Catalyst Watch: Earnings blitz, Fed speakers, and notable healthcare conferences

In a report released today, Josh Baer from Morgan Stanley maintained a Hold rating on Asana (ASAN – Research Report), with a price target of $14.00...

Cautious Hold Rating on Asana Amid AI Innovations and Market Uncertainties

The TipRanks All-star Analyst of the Day title goes to analyst Alex Zukin of Wolfe Research. Remarkably, Zukin ranks #70 out of the 9,147 Wall Stre...

TipRanks' All-Star Analyst – Who is the Best on MSFT Stock?

DA Davidson raised the firm's price target on Asana (ASAN) to $13 from $11 and keeps a Neutral rating on the shares. The company's Work Innovation ...

Asana price target raised to $13 from $11 at DA Davidson

D.A. Davidson analyst Lucky Schreiner maintained a Hold rating on Asana (ASAN – Research Report) today and set a price target of $13.00. The compan...

Asana (ASAN) Gets a Hold from D.A. Davidson

ALTM

AXNX

BIOX

BYON

CALM

CAMRF

DENN

ETON

FFIE

LOGI

MEDP

MNDY

MSFT

QCOM

RIVN

SMAR

TEAM

TMUS

UBER

WHLR

Press Releases

Asana Announces $150 Million Stock Repurchase Program

Asana to Announce Second Quarter Fiscal Year 2025 Financial Results on Tuesday, September 3, 2024

Asana Announces Fiscal 2024 ESG Report

Asana Announces Commitment to Pursuing FedRAMP Authorization

Asana Announces Second Quarter Fiscal 2025 Results

Asana Appoints Seasoned Finance Executive, Sonalee Parekh, as New Chief Financial Officer

Haymaker Group Expands Into San Francisco and Silicon Valley Markets, Building on A Decade of Impact Connecting Press with Tech Innovators and Investors

Asana Named a Leader in the 2024 Gartner® Magic Quadrant™ for Adaptive Project Management and Reporting

Asana Appoints Josh Abdulla as Head of Customer Experience

Asana Announces AI Studio: No-Code Builder for Designing and Deploying AI Agents in Critical Workflows

Comments

Asana

Noticias

Últimas noticias sobre Asana (NYSE:ASAN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL